	INFORMATION DISCLOSURE STATEMENT					
<u>-</u> ΔΤΤΥ.	DOCKET NUMBER VIS-0008-P2 SERIAL NUMBE	R FILED				
		ALMIC PREPARATION				
	AINING GLYCOMACROPEPTIDE					
	EXAMINER	ART UNIT				
1. 🗹	Applicant submits herewith a copy of (a) attached form PTO-1449, which lis submitted for consideration by the Office; (b) a legible copy of each document	sts all patents, publications, applications, or other information t required by 37 C.F.R. §1.98(b)(2).				
2. 🗹	Applicant herein apprises the Patent Office of references cited in a parent U.S. applicant date under 35 U.S.C. §120. The Serial Number of the parent application filed CCT. 3-2502 and entitled Gly coprotein and for Computing the publications cited therein are listed on attached Form PTO-1449. In accourse not required. Additional parent patent applications are listed on an attached Form PTO-1449.	n is U.S. Application PCT/USO2/31657  FlycomacropePtide rdance with 37 C.F.R. §1.98(d) copies of the listed publications				
3.	In accordance with 37 C.F.R. §1.98(a)(3), Applicant hereby certifies that for e  A copy of a translation of one or more non-English document, or portion  A concise explanation is (check at least one box below):  provided in the accompanying foreign or international search report;	thereof, is provided herewith;				
4. 🗹	§1.97(b)(1), (b)(2) – WITHIN 3 MONTHS OF FILING OR ENTRY IN NATION. Since this Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an §1.97(e) is required.	of the filing date of the subject application or within three month: international application, no fee or certification under 37 C.F.R				
<b>37 C.F.R.</b> § 5. □	§1.97(b)(3), (b)(4) – PRIOR TO MAILING OF FIRST OFFICE ACTION OR FIRST. Since this Information Disclosure Statement is being filed before the mailing of a first Office action after the filing of a request for continued examination u §1.97(e) is required.	late of the first Office Action on the merits, or before the mailing				
37 C.F. R. 6. □ a. b.	. §1.97(c) – AFTER FIRST ACTION, BEFORE FINAL ACTION OR ALLOWA Since this Information Disclosure Statement is being filed outside of the perior of a Final Rejection or Notice of Allowance, this submission is being accomp	d provided for in 37 C.F.R. §1.97(b), but before the mailing date anied by (one of the following boxes must be checked): §1.17(p).				
37 C.F.R. §1.97(d) – AFTER FINAL REJECTION OR ALLOWANCE 7. Since this Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(c), but on or before payment of the issue fee and is accompanied by both the statement specified in 37 C.F.R. §1.97(e) and the fee set forth in 37 C.F.R. §1.17(p). (Box 8 or 9 mus be checked.)						
8.	In accordance with 37 C.F.R. §1.97(e)(1), Applicant's attorney certifies that e Statement was first cited in any communication from a foreign patent office in a to the filling of this Information Disclosure Statement.   The foreign or interrupt.	counterpart foreign application not more than three months pric				
9. 🗖	In accordance with 37 C.F.R. §1.97(e)(2), Applicant's attorney certifies that Statement was cited in a communication from a foreign patent office in a coun signing this certification after making reasonable inquiry, no item of information to any individual designated in 37 C.F.R. §1.56(c) more than three months pr	iterpart foreign application, and, to the knowledge of the persoi I contained in this Information Disclosure Statement was know				
10. 😭	In the event the Commissioner of Patents deems that any additional fee is reapplication, Applicant's attorneys authorize that such fee be charged to Depo	equired under 37 C.F.R. §§ 1.16 or 1.17 in connection with this is it Account No. $06-1130$ .				
11. Con	sideration of this Information Disclosure Statement is respectfully requested.					
Na	ame: Daniel F. Drexler	Registration Number 47,535				
Signa	ature	Date March 30, 2004				
sufficient	CATE OF MAILING OR TRANSMISSION: I hereby certify that this correspondence is a postage as first class mail in an envelope addressed to: Commissioner For Patents, Pled to the Patent and Trademark Office to Facsimile No.	being deposited with the United States Postal Service with O. Box 1450, Alexandria, VA 22313-1450, or [ ] facsimile on the date shown below.				

Date

March 30, 2004

Name

Signature

## ' INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional) VIS-0008-P2	Application Number
Applicant(s) EDWARD J. ELLIS, ET AL.	
Filing Date	Group Art Unit

	Filing Date			Group Art Unit					
				U.S. PAT	ENT DOCUMENTS				
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE OPRIATE
		5,578,586	11/26/96	Glonek,	et al.				
<del></del>		5,371,108	12/06/94	Korb, e	t al.				
		5,294,607	03/15/94	Glonek,	et al.				
-		5,278,151	01/11/94	Korb, e	t al.				
		4,914,088	04/03/90	Glonek,	et al.				
		4,818,537	04/04/89	Guo					
		4,804,539	02/14/89	Guo, et	al.				
		5,460,834	10/24/95	Bhagat					
		6,180,093	01/30/01	De, et a	<b>l.</b>			:	
5,075,104	5,075,104	12/24/91	Gressel, et al.						
		5,209,927	05/11/93	Gressel	, et al.				
	•			FOREIG	N PATENT DOCUMENT	s			
	REF DOCUMENT NUMBER		DATE	DATE COUNTRY		CLASS	SUBCLASS		slation
-				-				YES	NO
				:					
!									
	<u> </u>		_	OTHER	DOCUMENTS (Includia	na Author Title	Date, Pertinent Pa	iges, Etc.)	
	<del></del>	Stuart Patton et al · "	The Enithelial M			-			iophysica
		Acta 1241 (1995) pages	407-424	ucin, moo	I, of Milk, Mammary G		,		• •
		L.T. Pallesen, et al.; "I Full-Length cDNA Clo	Purification of Mone"; J. Dairy Sc	UC1 from I i. 84:2591-2	Bovine Milk-Fat Globul 598; American Diary So	es and Charact cience Associat	erization of a Co ion 2001	orrespondi	ng
EXAMINE	.R		. <u> </u>		DATE CONSIDERED				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## ' INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional) VIS-0008-P2	Application Number
Applicant(s) EDWARD J. ELLIS, ET AL.	
Filing Date	Group Art Unit

					Filing Date		Group Art Unit		
				U.S. PAT	ENT DOCUMENTS				
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	
		5,225,196	07/06/93	Robinso	on				
-	-	4,983,392	01/08/91	Robinso	on .				
		4,615,697	10/07/86	Robinso	on				
			04/04/95	Lang, et	t al.				
			05/02/00	Saettone, et al.					
		4,438,100	03/20/84	Balslev, et al.  Leahy, et al.  Leahy, et al.					
		6,281,192	08/28/01						
		6,429,194	08/06/02						
		4,615,697	10/07/86	Robinso	on				
		5,188,826	02/23/93	Chandr	asekaran, et al.				
		2002/0045582	04/18/02	Margol	in, et al.				
				FOREIG	N PATENT DOCUMENTS				
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	Tran. YES	slation NO
								11.5	
							-		
				<u> </u>					
				<u> </u>					ļ
			D.C. W. LOAD			Author, Title,	Date, Pertinent Pa	ges, Etc.)	
		International Search Re	port; PCT/US02	/31657; 03	March 2003				
			-						
EXAMINE	R			and the second s	DATE CONSIDERED				The second secon

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## \*EXAMINER INITIAL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) \*EVAMINER INITIAL \*EVAMINER Plant | FUJIHARA et al., Lactoferrin suppresses loss of corneal epithelial integrity in a rabbit short-term dry eye model. J. Ocul Pharmacol Ther. April 1998; 14(2):99-107. Abstract. Use of lactoferrin (glycoprotein isolatable from bovine milk whey, inherently autoclavable), in a concentration of 0.01 to 1% as a suggested opthlamic preparation for corneal epithelial integrity.

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KITIAL	FUJIHARA et al., Lactoferrin suppresses loss of corneal epithelial integrity in a rabbit short-term dry eye model. J. Ocu Pharmacol Ther. April 1998; 14(2):99-107. Abstract. Use of lactoferrin (glycoprotein isolatable from bovine milk whey, inherently autoclavable), in a concentration of 0.01 to 1% as a suggested opthlamic preparation for corneal epithelial inte (i.e. dry eye treatment).							
	CHU et al. Isolation and characterization of porcine milk lactoferrin. Am J Vet Res. July 1993; 54(7):1154-9 P. 1154, left column, first paragraph (lactoferrin "molecular mass is estimated to be between 72,000-85,000 daltons).							
	HWANGBO, et al. Purification and characterization of novel whey glycoprotein WGP-88 which binds to a monoclonal antibody to PAS-4 glycoprotein in the bovine milk fat globule membrane. Biosci Biotechnol Biochem. September 1997; 61(9): 1568-74 P. 1571, left column, 4th paragraph, glycoproteins WGP-88 contained a 17.1% carbohydrate and PAS-4 had 7.2%. P. 1568 discusses phospholipids and glycoproteins as constituents of bovine milk (which could be isolated alone or together).							
EXAMINER	DATE CONSIDERED							
	<u>-</u>							

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.